Copiktra (Duvelisib) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Copiktra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat non-Hodgkin lymphomas including small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), and follicular lymphoma. Copiktra is indicated in cases where lymphoma has relapsed or failed at least two previous therapies. Copiktra is also referred to by its drug name, duvelisib.

Copiktra is used as targeted therapy for lymphoma. Copiktra is a member of a class of drugs called kinase inhibitors. Copiktra is believed to work by inhibiting cell growth.

How do I take it?
Prescribing information states that Copiktra is taken orally twice a day.

Copiktra comes in the form of a capsule.

Side effects
The FDA-approved label for Copiktra lists common side effects including fever, fatigue, cough, upper respiratory infection, pain in the muscles or bones, nausea, diarrhea, intestinal inflammation, rash, and low blood cell counts.

Rare but serious side effects listed for Copiktra include liver damage, fetal harm in pregnant women, and life-threatening infections, skin reactions, gastrointestinal inflammation, and lung inflammation.

For more details about this treatment, visit:

Copiktra — Secura Bio

Targeted Therapy Drugs for Non-Hodgkin Lymphoma — American Cancer Society

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of use and Privacy policy.
Already a Member? Log in